NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER

Clinical trials for NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER trials appear

Sign up with your email to follow new studies for NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Promising Pre-Surgery combo targets aggressive breast cancer in older adults

Disease control Not yet recruiting

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to shrink tumors in elderly patients (age 70+) with early-stage HER2-positive breast cancer. The goal is to see if this approach can elimi…

Matched conditions: NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER

Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated Jun 10, 2026 13:27 UTC

NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER

Get alerted when new NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER trials appear

Promising Pre-Surgery combo targets aggressive breast cancer in older adults